Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clinical Pharmacogenetics Implementation Consortium | RCV000783656 | SCV000922179 | drug response | CYP2C19: no function | practice guideline | curation | ||
Eurofins Ntd Llc |
RCV000291495 | SCV000331713 | other | not provided | 2015-12-28 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000291495 | SCV001904711 | benign | not provided | 2018-08-06 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 22865819, 20549256, 21855977, 22344438, 25087612, 25525159, 23874401, 7969038, 24906606) |
OMIM | RCV000018397 | SCV000038679 | drug response | Mephenytoin, poor metabolism of | 2009-06-01 | no assertion criteria provided | literature only | |
OMIM | RCV000018398 | SCV000038680 | drug response | Proguanil, poor metabolism of | 2009-06-01 | no assertion criteria provided | literature only | |
Cardiology Department, |
RCV002280093 | SCV002568452 | drug response | Acute coronary syndrome | no assertion criteria provided | research | ||
Faculty of Pharmacy, |
RCV004813044 | SCV005438652 | drug response | Clopidogrel response | no assertion criteria provided | research | rs4986893 is a SNP in the CYP2C19 gene and is linked to poor clopidogrel metabolic activation. rs4986893 is associated with reduced enzyme activity of CYP2C19 and lower concentration of clopidogrel active metabolite. |